Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Undersök effektivitet och säkerhet av karisbamat som tilläggsbehandling för anfall associerade med LGS hos barn och vuxna

3 november 2026 uppdaterad av: SK Life Science, Inc.

En randomiserad, dubbelblind, placebokontrollerad studie för att undersöka effektiviteten och säkerheten av karisbamat (YKP509) som tilläggsbehandling för anfall associerade med Lennox-Gastaut syndrom hos barn och vuxna, med valfri öppen förlängning

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The secondary objectives are:

  • To evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the total number of seizures compared with placebo in pediatric and adult subjects diagnosed with Lennox Gastaut Syndrome (LGS)
  • Evaluate the safety, tolerability of carisbamate in the LGS population
  • Evaluate steady-state pharmacokinetics of carisbamate in subjects with Lennox Gastaut.

Studietyp

Interventionell

Inskrivning (Beräknad)

252

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Argentina
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina
        • Avslutad
        • Hospital de Ninos de La Santisma Trinidad
    • Mendoza Province
      • Mendoza, Mendoza Province, Argentina
        • Avslutad
        • Resolution Psychopharmacology Research Institute
  • Australien
      • Heidelberg, Australien
        • Rekrytering
        • Austin Hosptial
        • Huvudutredare:
          • Ingrid Scheffer, MD
      • Melbourne, Australien
        • Rekrytering
        • Alfred Health
        • Huvudutredare:
          • Patrick Kwan
      • Nedlands, Australien
        • Avslutad
        • Perth's Children Hospital
      • South Brisbane, Australien
        • Avslutad
        • Queensland Children's Hospital
  • Colombia
      • Barranquilla, Colombia
        • Indragen
        • Fundacion Hospital Universidad del Norte
      • Cali, Colombia
        • Indragen
        • Fundacion Valle del Lili/Clinic - Outpatient
      • Envigado, Colombia
        • Avslutad
        • CliniSalud del Sur S.A.S - Centro de Investigación
      • Medellín, Colombia
        • Avslutad
        • Hospital Pabloe Tubon Uribe
      • Medellín, Colombia
        • Avslutad
        • Institutio Neurologico de Colombia
  • Förenta staterna
    • California
      • Palo Alto, California, Förenta staterna, 94305
        • Rekrytering
        • Stanford University Hospital
        • Huvudutredare:
          • Brenda Porter, MD
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32209
        • Avslutad
        • University of Florida Health Science Center
      • Orlando, Florida, Förenta staterna, 32803
        • Avslutad
        • AdventHealth
      • Tampa, Florida, Förenta staterna, 33609
        • Rekrytering
        • Pediatric Epilepsy and Neurology Specialists
        • Huvudutredare:
          • Jose Ferreira, MD
      • Tampa, Florida, Förenta staterna, 33620
        • Avslutad
        • University of South Florida
      • Wellington, Florida, Förenta staterna, 33414
        • Avslutad
        • Axcess Medical Research
    • Idaho
      • Boise, Idaho, Förenta staterna, 83702
        • Avslutad
        • Consultants in Epilepsy and Neurology PLLC
    • Kentucky
      • Lexington, Kentucky, Förenta staterna, 40504
        • Avslutad
        • Bluegrass Epilepsy Research, LLC
    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Avslutad
        • University Medical Center New Orleans
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Rekrytering
        • Johns Hopkins Hospital
        • Huvudutredare:
          • Joon Yi Kang, MD
      • Bethesda, Maryland, Förenta staterna, 20817
        • Rekrytering
        • Mid-Atlantic Epilepsy and Sleep Center
        • Kontakt:
          • Arkady Barber
        • Huvudutredare:
          • Pavel Klein, MD
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Avslutad
        • Mayo Clinic
    • Missouri
      • Columbia, Missouri, Förenta staterna, 65211
        • Avslutad
        • University of Missouri School of Medicine
    • New Jersey
      • Hackensack, New Jersey, Förenta staterna, 07601
        • Rekrytering
        • Northeast Regional Epilepsy Group
        • Huvudutredare:
          • Eric Segal, MD
      • New Brunswick, New Jersey, Förenta staterna, 08901
        • Avslutad
        • St. Peters Hospital
    • New York
      • The Bronx, New York, Förenta staterna, 10467
        • Avslutad
        • Montefiore
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27713
        • Rekrytering
        • Duke University Clinical Research at Pickett Road
        • Huvudutredare:
          • Muhammad Zafar, MD
      • Winston-Salem, North Carolina, Förenta staterna, 27101
        • Avslutad
        • Wake Forest University - School of Medicine
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Rekrytering
        • Children's Hospital of Philadelphia
        • Huvudutredare:
          • Eric Marsh, MD
    • Texas
      • Austin, Texas, Förenta staterna, 78758
        • Avslutad
        • Austin Epilepsy Care Center - Clinic/Outpatient Facility
      • Dallas, Texas, Förenta staterna, 75231
        • Avslutad
        • Neurology Consultants of Dallas, PA - Hospital
    • Virginia
      • Winchester, Virginia, Förenta staterna, 22601
        • Avslutad
        • Virginia Epilepsy and Neurodevelopmental Clinic at WNC
  • Grekland
    • Attica
      • Marousi, Attica, Grekland
        • Avslutad
        • Iaso Children's Hospital
  • Israel
      • Beersheba, Israel
        • Avslutad
        • Soroka University Medical Centre
      • Jerusalem, Israel, 91220
        • Avslutad
        • Hadassah Medical Center
      • Ramat Gan, Israel
        • Avslutad
        • Sheba Medical Center
    • Tel Aviv
      • Tel Aviv, Tel Aviv, Israel
        • Avslutad
        • Tela Viv Sourlasky Medical Center
  • Italien
      • Florence, Italien
        • Avslutad
        • Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN
      • Milan, Italien
        • Avslutad
        • ASST Santi Paolo E Carlo - Azienda Universitaria-Polo Universitaria - San Paolo
    • Liguria
      • Genoa, Liguria, Italien
        • Rekrytering
        • Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN
        • Huvudutredare:
          • Pasquale Striano, MD
    • Lombardy
      • Milan, Lombardy, Italien
        • Rekrytering
        • ASST Fatebenefratelli Sacco - Ospedale dei Bambini Vittore Buzzi
        • Huvudutredare:
          • Monica Lodi, MD
      • Milan, Lombardy, Italien
        • Rekrytering
        • Fondazione IRCCS Di Rilievo Nazionale Instituto
        • Huvudutredare:
          • Elena Freri, MD
    • Verona
      • Verona, Verona, Italien
        • Rekrytering
        • Azienda Ospedaliera Universitaria Integrata Di Verona
        • Huvudutredare:
          • Francesca Darra, MD
  • Mexiko
      • Culiacán, Mexiko
        • Rekrytering
        • Neurociencias Estudios Clinicos S.C.
        • Huvudutredare:
          • Elmer Lopez Meza, MD
      • Mexico City, Mexiko, 06700
        • Rekrytering
        • Clinstile, S.A. de C.V.
        • Huvudutredare:
          • Sandra Quinones, MD
    • Jalisco
      • Guadalajara, Jalisco, Mexiko
        • Rekrytering
        • Hospital Civil Fray Antonio Alcalde
        • Huvudutredare:
          • Hugo Ceja Moreno, MD
  • Polen
      • Krakow, Polen
        • Rekrytering
        • Centrum Medyczne Plejady
        • Huvudutredare:
          • Marta Zolnowska, MD
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, Polen
        • Avslutad
        • Szpital Kliniczny im.H.Swiecickiego Uniwersytetu Medycznego im.K.Marcinkowskiego w Poznaniu-Dluga1/2
  • Portugal
    • Lisbon District
      • Lisbon, Lisbon District, Portugal
        • Rekrytering
        • Centro Hospitalar de Lisboa Norte, EPE
        • Huvudutredare:
          • Sofia Quintas, MD
      • Lisbon, Lisbon District, Portugal
        • Avslutad
        • Centro Hospitalar de Lisboa Ocidental, EPE - Hospital Sao Francisco Xavier
    • Porto District
      • Porto, Porto District, Portugal
        • Rekrytering
        • Centro Hospitalar de Sao Joao, EPE
        • Huvudutredare:
          • Raquel Sousa, MD
    • Setúbal District
      • Almada, Setúbal District, Portugal
        • Avslutad
        • Hospital Garcia de Orta
  • Serbien
      • Belgrade, Serbien
        • Rekrytering
        • University Clinical Center of Serbia - PPDS
        • Huvudutredare:
          • Dragoslav Sokic, MD
      • Kragujevac, Serbien
        • Rekrytering
        • University Clinical Center Kragujevac
        • Huvudutredare:
          • Aleksandar Gavrilovic, MD
      • Niš, Serbien
        • Rekrytering
        • University Clinical Center Nis
        • Huvudutredare:
          • Tatjana Tosic, MD
      • Novi Sad, Serbien
        • Rekrytering
        • Children and Youth Health Care Institute of Vojvodina
        • Huvudutredare:
          • Marija Knezevic-Pogancev, MD
        • Kontakt:
          • Tatjana Redzek Mudrinic, MD
    • Belgrade
      • Belgrade, Belgrade, Serbien
        • Rekrytering
        • Childrens University Hospital
        • Huvudutredare:
          • Dimitrije Nikolic, MD
  • Spanien
      • Madrid, Spanien
        • Rekrytering
        • Hospital Ruber Internacional (Grupo Quironsalud)
        • Huvudutredare:
          • Antonio Gil-Nigel, MD
      • Madrid, Spanien
        • Avslutad
        • Hospital Infantil Universitario Niño Jesus - PIN
    • Barcelona
      • Esplugues de Llobregat, Barcelona, Spanien
        • Avslutad
        • Hospital Sant Joan de Deu - PIN
  • Sydkorea
      • Daegu, Sydkorea
        • Avslutad
        • Kyungpook National University Chilgok Hospital
      • Seoul, Sydkorea
        • Rekrytering
        • Samsung Medical Center
        • Huvudutredare:
          • Jee Hun S. Lee, MD
      • Seoul, Sydkorea
        • Rekrytering
        • Seoul National University Hospital
        • Huvudutredare:
          • Byung Chan Lim, MD
  • Taiwan
      • Taipei, Taiwan
        • Rekrytering
        • Taipei Veterans General Hospital
        • Huvudutredare:
          • Ting-Rong Hsu, MD
      • Taipei, Taiwan
        • Rekrytering
        • National Taiwan University Hospital
        • Huvudutredare:
          • Wang-Tso Lee, MD
      • Taoyuan, Taiwan
        • Avslutad
        • Chang Gung Memorial Hospital
  • Tyskland
    • Bavaria
      • Erlangen, Bavaria, Tyskland
        • Rekrytering
        • Universitatsklinikum Erangen
        • Huvudutredare:
          • Hajo Martinus Hamer, MD
    • Saxony
      • Radeberg, Saxony, Tyskland
        • Rekrytering
        • Kleinwachau Sächsisches Epilepsiezentrum
        • Huvudutredare:
          • Nils Holert, MD
  • Ungern
      • Budapest, Ungern
        • Avslutad
        • Orszagos Mentalis, Ideggyogyaszati es Idegsebezeti Intezet
      • Budapest, Ungern
        • Rekrytering
        • Semmelweis Egyetem Idegsebeszeti es Neurointervencios Klinika
        • Kontakt:
          • Anna Sakovics, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

4 år till 55 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Subject must have a documented history of Lennox-Gastaut syndrome by:

    1. Evidence of more than one type of seizure, of which at least one should be an atonic or tonic seizure
    2. History of an electroencephalogram (EEG) reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow, spike and wave pattern <3.0 Hz)
    3. History of developmental delay

  2. Male or female subjects

  3. Subjects must be age 4-55 years at the time of consent/assent

  4. Must have been <11 years old at the onset of LGS

  5. Subjects must have experienced at least 2 drop seizures with potential to fall (tonic, atonic, tonic-clonic) during the 4-week Baseline period preceding randomization (minimum of 4 drop seizures in the first two weeks and 4 in the last two weeks). Drop seizures are defined as a seizure involving the entire body, trunk, or head that led or could have led to a fall, injury, slumping in a chair, or hitting the subject's head on a surface. All drop seizure types must be countable (either as isolated seizures or as countable isolated seizures in a cluster).

  6. Subjects must have been receiving 1 to 4 concomitant anti-seizure medications (ASMs) at a stable dose for at least 4 weeks before Visit 1

  7. If not taking Epidiolex, subjects may take other approved cannabidiol or over the counter cannabidiol products. If taking cannabidiol other than Epidiolex, consult Medical Monitor to determine if it counts as a concomitant ASM.

  8. Dietary therapy and any CNS stimulator settings must be stable for 4 weeks prior to baseline and maintain stable regimen throughout the study. The dietary therapy and CNS stimulators are not counted as an ASM.

  9. Parents or caregivers must be able to keep accurate seizure diaries

  10. Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), if of childbearing potential, must comply with an acceptable method of birth control during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study, if able.

  11. Subject and/or caregiver(s)/legal representative must be willing and able to give informed assent/consent for participation in the study

  12. Subject and their caregiver must be willing and able (in the investigator's opinion) to comply with all study requirements

  13. History of COVID-19 vaccination is permitted

Exclusion Criteria:

  1. Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation, unless there is a progressive brain tumor
  2. Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the subject's safety or study conduct
  3. Subjects who were on adrenocorticotropic hormone (ACTH) therapy in the 6 months prior to baseline
  4. Subject on dietary therapy for less than 4 weeks prior to screening visit (Visit 1) or suffers from frequent stooling
  5. Current use of felbamate with less than 18 months of continuous exposure
  6. Concomitant use of vigabatrin: subjects who took vigabatrin in the past must be discontinued for at least 5 months before Visit 1 and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test, if able.
  7. Subject who had a history of hypoxia which needed emergency resuscitation within 12 months prior to baseline
  8. Status epilepticus within 12 weeks prior to Visit 1
  9. Any clinically significant illness (including COVID-19) in the 4 weeks prior to Visit 1, as evaluated by the Investigator
  10. Subject has clinically significant abnormal laboratory values, in the investigator's opinion, at Visit 1 or time of randomization (Visit 2)
  11. Subject has a history of any serious drug-induced hypersensitivity, e.g., toxic epidermal necrolysis, or Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring hospitalization
  12. Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Responsive Neurostimulator System (RNS) or other neurostimulation for epilepsy device implanted or activated <5 months year prior to enrollment. Stimulation parameters that have been stable for <4 weeks, or Battery life of unit not anticipated to extend for duration of trial.
  13. Subject is pregnant, may be pregnant, lactating or planning to be pregnant
  14. Any suicidal ideation with intent, with or without a plan within 6 months before Visit 2 (i.e., answering "Yes" to questions 4 or 5 in the Suicidal Ideation section of the age- specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated
  15. Any suicidal behavior within 2 years before Visit 2 (i.e., answering YES to any question in the Suicidal behavior section of the age-specific Columbia-Suicide Severity Rating Scale (C-SSRS) in subjects aged 6 and above who are able to be evaluated.
  16. Evidence of significant active hepatic disease. Stable elevations of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) due to concomitant medication(s) will be allowed if they are <3 x ULN
  17. Subject with total bilirubin [TBL] >2 x ULN (except for Gilbert's syndrome).
  18. Active viral hepatitis (B or C) as demonstrated by positive serology at the Screening visit (Visit 1)
  19. History of positive antibody/antigen test for human immunodeficiency virus (HIV)
  20. If taking Epidiolex, subject may not use other approved cannabidiol or over the counter cannabidiol products
  21. Scheduled for epilepsy-related surgery, VNS insertion, or any other stimulators/surgery during the projected course of the study
  22. Subject who has taken or used any investigational drug or device in the 4 weeks prior to the screening visit (Visit 1)
  23. Concomitant use of medications known to be strong inducers of cytochrome P450 (CYP3A) including, but not limited to: phenobarbital, phenytoin, carbamazepine, primidone, rifampin, troglitazone, St. John's Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin
  24. Evidence of cardiac disease, including unstable angina, myocardial infarction, within the past 2 years, uncontrolled heart failure, major arrhythmias, congenital short QT syndrome
  25. Subject with a short QTc interval (<340 msec) or long QTc interval (>460 msec) as confirmed by a repeated electrocardiogram (ECG)
  26. Benzodiazepine rescue administered on average more than once a week in the month before Visit 1
  27. Previous exposure to carisbamate or sensitivity/allergy to components of the oral suspension.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Carisbamate 200 mg BID arm

Age: 4 to <12y* Titration: 2 mg/kg BID Maintenance: 4 mg/kg BID

Age: ≥12 y Titration: 100 mg BID Maintenance: 200 mg BID
Läkemedel: Carisbamate

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).
Experimentell: Carisbamate 300 mg BID arm

Age: 4 to <12y* Titration: 2.75 mg/kg BID Maintenance: 5.5 mg/kg BID

Age: ≥12 y Titration: 150 mg BID Maintenance: 300 mg BID
Läkemedel: Carisbamate

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).
Placebo-jämförare: Placebo matched to 200 mg BID arm

Age: 4 to <12y* Titration: Volume equivalent to 2 mg/kg BID Maintenance: Volume equivalent to 4 mg/kg BID

Age: ≥12 y Titration: Volume equivalent to 100 mg BID Maintenance: Volume equivalent to 200 mg BID
Läkemedel: Carisbamate

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).
Placebo-jämförare: Placebo matched to 300 mg BID arm

Age: 4 to <12y* Titration: Volume equivalent to 2.75 mg/kg BID Maintenance: Volume equivalent to 5.5 mg/kg BID

Age: ≥12 y Titration: Volume equivalent to 150 mg BID Maintenance: Volume equivalent to 300 mg BID
Läkemedel: Carisbamate

Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to < 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID [or a total of 400 mg per day]).

Subjects 4 to < 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID [or a total of 600 mg per day]).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Primary outcome will be the percentage change from baseline in the total frequency (average per 28 days) of countable drop seizures with potential to fall (tonic, atonic, tonic-clonic) seizures during the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The percentage of subjects with at least a 50% reduction from baseline in the total frequency of drop seizures (tonic, atonic, tonic-clonic) during the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
Percentage change from baseline in the frequency of all types of seizures (total seizures) during the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
Subject/Caregiver Global Impression of Change (S/CGIC) in overall condition score at the last visit.
Tidsram: 3 years

Efficacy of Carisbamate YKP509- Scoring will be from 1 to 7 with 1 (very much improved) to 7 (very much worse)
3 years

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage change from baseline in the 28-day frequency of: drop seizures (tonic, atonic, tonic-clonic); non-drop seizures (myoclonic seizures, atypical absence); total seizures during the maintenance phase of the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
Percentage change from baseline in non-drop seizures (myoclonic seizures, atypical absence) frequency per 28 days during the during the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
The percentage of subjects with at least a 50% reduction from baseline in the total frequency of drop seizures (tonic, atonic, tonic-clonic) during the maintenance phase of the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
Proportion of subjects with a 75%, 90% and 100% response rate for drop seizures (tonic, atonic, tonic-clonic), non-drop seizures, and total seizures during the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years
Proportion of subjects with a 75%, 90% and 100% response rate for drop seizures (tonic, atonic, tonic-clonic), non-drop seizures, and total seizures during the maintenance phase of the double-blind treatment period.
Tidsram: 3 years

Efficacy of Carisbamate YKP509
3 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

SK Life Science, Inc.

Utredare

  • Studierektor: Marc Kamin, MD, SK Life Science, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

28 april 2022

Primärt slutförande (Beräknad)

1 februari 2027

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

6 januari 2022

Först inskickad som uppfyllde QC-kriterierna

20 januari 2022

Första postat (Faktisk)

2 februari 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • YKP509C003

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera